Efficacy of Tralokinumab for treatment of atopic dermatitis
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Atopic dermatitis occurs when the barrier function of the skin is disrupted, allowing chemicals and allergens to enter the skin and cause inflammation. Tralokinumab is a drug injected under the skin that targets interleukin (IL) 13, a molecule that is important in causing the skin inflammation associated with atopic dermatitis.

Two identically designed clinical trials, ECZTRA 1 and ECZTRA 2, investigated if tralokinumab alone was more effective than a nonactive drug for improving the severity and symptoms of atopic dermatitis.

Adult patients who had moderate to severe atopic dermatitis for more than 1 year that had not improved sufficiently with topical treatments were included. Patients received tralokinumab 300 mg or placebo every 2 weeks for an initial 16 weeks. Patients who showed a good response to tralokinumab either continued with the same treatment, received less frequent dosing of tralokinumab (once every 4 weeks), or received placebo for a further 36 weeks to assess long term safety. The medical team also documented the occurrence of any side effects of the drug.

--In both trials at week 16, more patients receiving tralokinumab had an improvement in their atopic dermatitis compared with patients receiving placebo.

--Patients felt meaningful improvements in itch, sleep and quality of life as early as 1–2 weeks after starting tralokinumab.

--The majority of patients who had high levels of improvement at week 16 with tralokinumab maintained that level of improvement after another 36 weeks of treatment with dosing every 2 weeks.

--In addition, some patients maintained their improved skin with less frequent dosing every 4 weeks.

--The most common side effects with tralokinumab were upper respiratory tract infections (mainly common cold) and conjunctivitis (inflammation of the eye or eyelid).

In particular, Trolokinumab may be a long-term treatment choice for adult patients with mild to extreme atopic dermatitis, based on the findings of these studies.

Source: https://onlinelibrary.wiley.com/doi/10.1111/bjd.19778?af=R